Journals / Turkish Journal of Pediatrics / 2021 / Cilt: 63 - Sayı: 5

Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors

Pages
758–766
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to establish the importance and effects of PD-1/PD-L1 pathway in pediatric tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells.
📊
Key Findings & Data:It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2).
💡
Conclusion & Impact:Further studies are needed to establish the importance and effects of PD-1/PD-L1 pathway in pediatric tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2). T cell functions are inhibited by activation of PD-1/PD-L1 pathway and this pathway is used by viruses and some tumor cells in order to escape from immune eradication. In our study we evaluated PD-L1 expression in the tissue specimens of patients with Wilms tumor, neuroblastoma and other renal tumors. Methods. Totally 60 patients who were followed up at Gazi University Hospital with the diagnosis of neuroblastoma, Wilms tumor and other renal tumors were included. PD-L1 expression was examined in tumor samples of the patients. Results. Positive staining with PD-L1 was detected only in two male patients. Both of them had neuroblastoma and advanced stage disease. None of the patients with Wilms tumor and other renal tumors had positive PD-L1 staining. Conclusions. Unlike adult tumors, PD-L1 expression is not common in childhood tumors due to differences in immune system between children and adults. Further studies are needed to establish the importance and effects of PD-1/PD-L1 pathway in pediatric tumors.

🔖

Cite This Article

ŞENER, S., OKAR, A., PINARLI, F. G., KARADENİZ, C., POYRAZ, A. (2021). Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 5, 758–766. https://ajindex.com/articles/411763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Keir M, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 2008; 26: 677-704
  2. Latchman Y, Wood C, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268
  3. Tseng S, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-845
  4. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297
  5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443- 2454
  6. Herbst RS, Soria JS, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567. 7. van Dam LS, de Zwart VM, Meyer-Wentrup FA. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Pediatr Blood Cancer 2014; 62: 190-197
  7. Aksoylar S, Varan A, Vergin C, et al. Treatment of high-risk neuroblastoma: National protocol results of the Turkish Pediatric Oncology Group. J Can Res Ther 2017; 13: 284-290
  8. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-372
  9. Bertolini G, Bergamaschi L, Ferrari A, et al. PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer 2018; 18: 652
  10. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19: 1021-1034
  11. Afreen S, Dermine S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 2014; 7: 1-17
  12. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11: 2947- 2953
  13. Routh JC, Ashley RA, Sebo TJ, et al. B7-H1 expression in Wilms tumor: correlation with tumor biology and diseaser currence. J Urol 2008; 179: 1954-1960
  14. Uehara S, Nakahata K, Kawatsu M, et al. The PD-L1 expression increases after consecutive multimodal therapeies in neuroblastoma. Pediatr Blood Cancer 2015; 62: S334
  15. Chowdhury F, Dunn S, Mitchell S, Mellows T, Ashton-Ke